|
Physiomics PLC on Tuesday said that it has been awarded a new contract by an existing, large pharmaceutical client. Physiomics is an Abingdon, Oxfordshire-based mathematical modelling company that supports oncology drug development. Its shares were trading 1.3% lower at 0.67 pence each in London on Tuesday afternoon. The project, it explained, is worth £65,000, and involves updating two models previously created for the client with newly generated clinical data. These models are based on Physiomics’ proprietary Virtual Tumour platform and are developed to support dosing and scheduling decisions for the client’s oncology combination therapies. It is expected that the contract will be completed over the course of the year. ‘We are delighted to have been awarded this new contract with one of our existing clients. This win is testament to the quality and impact of the services we provide and the longevity of our client relationships,’ said Chief Executive Officer Peter Sargent. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
